Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867695 | 1.00 | PRCP (0.35) | PRCPMEN1KMT2ACACNA2D1NPSR1 | |
| SCHEMBL4867698 | 1.00 | PRCP (0.35) | PRCPMEN1KMT2ACACNA2D1NPSR1 | |
| SCHEMBL4868529 | 0.86 | GSK3B (0.36) | MEN1KMT2ANPSR1ALDH1A1ADORA2A | |
| SCHEMBL4868527 | 0.86 | GSK3B (0.36) | MEN1KMT2ANPSR1ALDH1A1ADORA2A | |
| SCHEMBL4868520 | 0.86 | GSK3B (0.36) | MEN1KMT2ANPSR1ALDH1A1ADORA2A | |
| SCHEMBL4869668 | 0.78 | DPP4 (0.39) | MEN1KMT2ANPSR1ALDH1A1TDP1 | |
| SCHEMBL7014250 | 0.77 | ADORA2B (0.36) | ADORA2AMAOBADORA2BKDM1A | |
| SCHEMBL4875113 | 0.76 | GSK3B (0.38) | MEN1KMT2ANPSR1ALDH1A1ADORA2A | |
| SCHEMBL4875105 | 0.76 | GSK3B (0.38) | MEN1KMT2ANPSR1ALDH1A1ADORA2A | |
| SCHEMBL4875095 | 0.76 | GSK3B (0.38) | MEN1KMT2ANPSR1ALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214682-B2 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | claimed |
| EP-1430057-B1 | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO 1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO 1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-08-31 | — | — | EP | claimed |
| US-20050049261-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI (FR) | 2005-03-03 | — | — | US | claimed |
| EP-1430057-A2 | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO 1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO 1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | Sanofi-Aventis (FR) | 2004-06-23 | — | — | EP | claimed |
| EP-1340761-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | claimed |
| WO-2003027116-A2 | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | claimed |
| EP-1295885-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-03-26 | — | — | EP | claimed |
| US-7462621-B2 | Use of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives as therapeutic agents | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-20070167461-A1 | USE OF SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES AS THERAPEUTIC AGENTS | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7214682-B2 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| EP-1674456-A2 | Substituted alpha-halo-beta-keto-pyridinylpropanoates | Sanofi-Aventis (FR) | 2006-06-28 | — | — | EP | disclosed |
| EP-1430057-B1 | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO 1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO 1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2005-08-31 | — | — | EP | disclosed |
| US-20050049261-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI (FR) | 2005-03-03 | — | — | US | disclosed |
| EP-1430057-A2 | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO 1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO 1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | Sanofi-Aventis (FR) | 2004-06-23 | — | — | EP | disclosed |
| EP-1340761-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003027116-A2 | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | disclosed |
| EP-1295885-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167461-A1 | USE OF SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES AS THERAPEUTIC AGENTS | CDK5, CDK5R1, PSEN2 | PRCP 549/4885MEN1 3044/4885KMT2A 2307/4885 |
| US-20050049261-A1 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | CDK5, PSEN1, GSK3A | PRCP 3119/4885MEN1 4420/4885KMT2A 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.